Skip to main content
      ACR Best Abstracts - Day 1

      The RheumNow faculty reporters have been scouring the meeting and online presentations to f

      Dr. John Cush RheumNow

      3 years 1 month ago
      ACR Best Abstracts - Day 1 The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest). https://t.co/ndSBqYszlo https://t.co/vOHtLTFux6
      RT @synovialjoints: Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors,

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ
      RT @synovialjoints: New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via i

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu
      RT @RHEUMarampa: How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎

      sheila RHEUMarampa

      3 years 1 month ago
      How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎 Remember this important slide👇 #ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt
      RT @RHEUMarampa: Statin therapy may exacerbate underlying neuromuscular disorders.
      ‼️REMEMBER☝️The only ABSOLUT

      sheila RHEUMarampa

      3 years 1 month ago
      Statin therapy may exacerbate underlying neuromuscular disorders. ‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+ #ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X
      RT @RHEUMarampa: Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction:

      sheila RHEUMarampa

      3 years 1 month ago
      Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction: 🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts. #ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A
      RT @RHEUMarampa: In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psor

      sheila RHEUMarampa

      3 years 1 month ago
      In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials 🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies #ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5
      RT @RHEUMarampa: Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team:
      💊Pts on UPA showed gre

      sheila RHEUMarampa

      3 years 1 month ago
      Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team: 💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits 💊Pts on UPA had better responses in all assessments vs. PBO Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf
      RT @AkhilSoodMD: Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA

      Akhil Sood MD AkhilSoodMD

      3 years 1 month ago
      Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved -Sensitivity 82%; specificity 81% -PPV 0.89; NPV 0.70 https://t.co/PDSsiMIQUc @RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ
      RT @AkhilSoodMD: Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD)
      - VR naïve &am

      Akhil Sood MD AkhilSoodMD

      3 years 1 month ago
      Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD) - VR naïve & experienced were willing to use VR to manage their RD - VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD @RheumNow #ACR22 https://t.co/r7X8Kqp8UN
      RT @ericdeinmd: Abst0338 #ACR22 Transition from CLE to SLE
      324 cases of incident cutaneous lupus, mean f/u 8 years
      26 pt

      Eric Dein ericdeinmd

      3 years 1 month ago
      Abst0338 #ACR22 Transition from CLE to SLE 324 cases of incident cutaneous lupus, mean f/u 8 years 26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years Risk factors: SCLE, younger age, recent diagnosis @RheumNow #ACRBest https://t.co/JFcUIkfA9n
      RT @ericdeinmd: Year in Review #ACR22
      Pre-expos PPx for COVID!
      Tix-Cil (Evusheld): risk reduction 77%
      Cardiac AES 0.6% v

      Eric Dein ericdeinmd

      3 years 1 month ago
      Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow
      RT @ericdeinmd: Ab1291 #ACR22: 🔥Ignite🔥
      @DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab1291 #ACR22: 🔥Ignite🔥 @DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77) Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺 3 mo pilot program predictive @RheumNow https://t.co/Iey87SVGv4
      ×